바로가기메뉴

본문 바로가기 주메뉴 바로가기
 

logo

메뉴

Preimplantation Genetic Testing for Rare Monogenic Disease: A Female Reproductive Medicine Perspective on the Clinical Pathway

Abstract

Preimplantation genetic testing for monogenic disorders (PGT-M) allows couples at high risk of transmitting a rare genetic disease to achieve an unaffected pregnancy while substantially reducing the likelihood of pregnancy termination after prenatal diagnosis. Although PGT-M is often presented as a molecular genetic technique, its clinical success also depends on reproductive variables: ovarian reserve, ovarian response to controlled stimulation, blastocyst yield, and obstetric management of the resulting pregnancy. This review follows the PGT-M pathway chronologically, from genetic diagnosis and pre-cycle workup through ovarian stimulation, embryo biopsy and genetic analysis, embryo transfer, and confirmatory prenatal diagnosis, and considers each step from the perspective of female reproductive medicine. Particular attention is given to the embryo attrition cascade that determines whether a transferable embryo will be available; the interpretation of outcomes per couple rather than per transfer; carrier states in which the pathogenic variant itself compromises ovarian function; and the counseling and regulatory framework applicable in Korea. PGT-M is best regarded not as a laboratory service but as a multidisciplinary program in which clinical genetics, the PGT laboratory, embryology, reproductive medicine, and obstetric care each contribute to the goal of a healthy live birth.

keywords
Preimplantation diagnosis; Genetic testing; Rare diseases; Genetic counseling; Fertilization in vitro

Received
2026-09-15
Revised
2026-10-03
Accepted
2026-10-16
Published
2026-10-31

logo